Associated Papers
Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid.
Peng Y et al.
Molecular Medicine (cambridge, Mass.), 2025
40247187 (PubMed )
Supplement: 10020_2025_1199_MOESM5_ESM.xlsx › Sheet1
Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential.
Alors-Pérez E et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2023
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Toribio-Castelló S et al.
Cancers, 2023
37568638 (PubMed )
Supplement: cancers-15-03822-s001.zip › Supplementary_tables.xlsx › Table_S2
Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?
Yu J et al.
Npj Breast Cancer, 2023
37443169 (PubMed )
Supplement: 41523_2023_566_MOESM1_ESM.pdf
Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer.
He W et al.
Biomarker Insights, 2022
36533271 (PubMed )
Supplement: sj-xlsx-2-bmi-10.1177_11772719221141525.xlsx › mutation_list_of_the_former_22_
SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
Yang JY et al.
Molecular Oncology, 2021
Mutations driving CLL and their evolution in progression and relapse.
Landau DA et al.
Nature, 2015
26466571 (PubMed )
Supplement: NIHMS715090-supplement-Supplementary_Table_10.xlsx › CCF_DP_clustering
Select a paper to view details